|
Cloprostenol Injection
» Cloprostenol Injection is a sterile solution of Cloprostenol Sodium in Water for Injection. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of cloprostenol (C22H29ClO6).
Packaging and storage
Preserve in single-dose or multiple-dose containers protected from light. Store at controlled room temperature.
Labeling
Label it to indicate that it is for veterinary use only, and to indicate the strength as the equivalent amount of cloprostenol per dose.
USP Reference standards
USP Endotoxin RS
Identification
A:
The retention time of the cloprostenol peak in the chromatogram of the Assay preparation corresponds to that of the cloprostenol peak in the chromatogram of the Standard preparation, obtained as directed in the Assay.
B:
It meets the requirements of the test for Sodium
Bacterial endotoxins
Sterility
Related compounds
Mobile phase and System suitability solution
Prepare as directed in the Assay.
Standard solution
Prepare as directed for Standard preparation under Assay.
Test solution
Prepare as directed for Assay preparation.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 20 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure all of the peak responses. Calculate the percentage of each impurity in the portion of Injection taken by the formula:
100(CS / CT)(ri / rS)
in which CS is the concentration, in mg per mL, of USP Cloprostenol Sodium RS in the Standard solution; CT is the concentration, in mg per mL, of cloprostenol in the Test solution; ri is the peak response for each impurity obtained from the Test solution; and rS is the peak response of cloprostenol obtained from the Standard solution: not more than 1.0% of any individual impurity is found, and not more than 2.5% of total impurities is found. Disregard any peak below 0.05%.
Other requirements
It meets the requirements under Injections
Assay
pH 2.5 Monobasic sodium phosphate solution
Prepare an aqueous solution containing 2.4 mg of monobasic sodium phosphate dihydrate per mL of solution. Adjust with phosphoric acid to a pH of 2.5.
Mobile phase
Prepare a filtered and degassed mixture of pH 2.5 Monobasic sodium phosphate solution and acetonitrile (73:27). Make adjustments if necessary (see System Suitability under Chromatography
System suitability solution
Dissolve an accurately weighed quantity of USP Cloprostenol Sodium RS and USP Hydrocortisone Acetate RS in dehydrated alcohol, and dilute with Mobile phase to obtain a solution containing about 0.25 mg of cloprostenol sodium and 0.5 mg of hydrocortisone acetate per mL of solution.
Standard preparation
Dissolve an accurately weighed quantity of USP Cloprostenol Sodium RS in dehydrated alcohol, and dilute quantitatively, and stepwise if necessary, with dehydrated alcohol to obtain a solution having a known concentration of about 0.1 mg per mL.
Assay preparation
Dilute a volume of Injection in dehydrated alcohol and dilute quantitatively, and stepwise if necessary, with dehydrated alcohol to obtain a solution containing 0.1 mg of cloprostenol per mL of solution, based on the label claim.
Chromatographic system (see Chromatography
Procedure
Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the cloprostenol peak. Calculate the percentage label claim of cloprostenol (C22H29ClO6) in the portion of Injection taken by the formula:
100(CS / CU)(rU / rS)(M1 / M2)
in which CS is the concentration, in mg per mL, of USP Cloprostenol Sodium RS in the Standard preparation; CU is the concentration, in mg per mL, of cloprostenol in the Assay preparation; rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively, M1 is the molecular weight of cloprostenol (424.92), and M2 is the molecular weight of cloprostenol sodium (446.90).
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 2737
Pharmacopeial Forum: Volume No. 34(4) Page 918
|